论文部分内容阅读
目的:评价化疗期间,出现中重度感染后应用比阿培南抗感染的疗效。方法:回顾性分析我科104例应用比阿培南的淋巴瘤合并中重度感染患者,予以比阿培南0.3-0.6 g/次,静脉滴注,1/8小时或1/12小时,治疗5-16天,观察其应用比阿培南后的临床疗效及不良反应。结果:治疗中度发热的患者31例,其中痊愈+显效28例,有效率为90.3%(28/31);治疗高热以上的患者73例,其中痊愈+显效56例,有效率为76.7%(56/73)。总有效率为80.8%。其中感染发生在IV度骨髓抑制期的有52例,痊愈+显效44例,有效率为84.6%。且104例患者中,仅1例发生皮肤过敏反应,其余未观察到明确的不良反应。结论:比阿培南在治疗淋巴瘤患者合并中重度感染的应用中,为安全有效的碳青霉烯类药物。
OBJECTIVE: To evaluate the efficacy of biapenem in anti-infectives after moderate and severe infections during chemotherapy. Methods: A retrospective analysis of 104 cases of Biapenem in our department with lymphoma with moderate to severe infection in patients with biapenem 0.3-0.6 g / time, intravenous infusion, 1/8 hours or 1/12 hours, treatment 5-16 days to observe the clinical efficacy and adverse reactions after application of biapenem. Results: 31 cases of moderate fever were cured, of which 28 cases were cured and markedly effective, with an effective rate of 90.3% (28/31); 73 cases were treated with hyperthermia, of which 56 cases were cured and markedly effective, with an effective rate of 76.7% 56/73). The total effective rate is 80.8%. Infection occurred in IV degree myelodysplastic phase in 52 cases, cured + markedly effective in 44 cases, the effective rate was 84.6%. And of the 104 patients, only 1 case of allergic skin reaction, the rest did not observe a clear adverse reactions. CONCLUSIONS: Biapenem is a safe and effective carbapenem for the treatment of patients with lymphoma with moderate to severe infections.